Add a GLP-1 Receptor Agonist to Metformin
After discontinuing the SGLT2 inhibitor due to recurrent UTIs, add a long-acting GLP-1 receptor agonist (such as dulaglutide, liraglutide, or semaglutide) to metformin for this patient.
Rationale for GLP-1 RA Selection
The KDIGO 2020 guidelines explicitly recommend that for patients with type 2 diabetes and CKD who cannot use SGLT2 inhibitors, a long-acting GLP-1 receptor agonist should be added to metformin 1. This recommendation is particularly strong (Grade 1B) and prioritizes agents with documented cardiovascular benefits 1.
Why Not Resume the SGLT2 Inhibitor?
While SGLT2 inhibitors like empagliflozin have excellent cardiovascular and renal benefits, recurrent UTIs represent a legitimate reason for discontinuation 1. The guidelines acknowledge that SGLT2 inhibitors increase the risk of genitourinary infections, with genital mycotic infections occurring in approximately 6% of patients 2. Although the evidence on whether to continue SGLT2 inhibitors after UTIs is mixed—with one recent study suggesting continuation may not increase recurrent UTI risk 3—the patient's quality of life and infection burden must be prioritized.
Specific GLP-1 RA Recommendations
Preferred agents with proven cardiovascular benefit 2:
- Dulaglutide (0.75-1.5 mg once weekly): No dose adjustment needed for renal impairment; can be used with eGFR >15 mL/min/1.73 m²
- Liraglutide (0.6-1.8 mg once daily): No dose adjustment required; proven MACE reduction
- Semaglutide (0.5-1 mg once weekly injectable, or 3-14 mg oral daily): No dose adjustment needed; strong cardiovascular outcomes data
Dosing Strategy
Start low and titrate slowly to minimize gastrointestinal side effects 1:
- Begin with the lowest available dose
- Increase gradually every 4 weeks based on tolerance
- GI symptoms (nausea, vomiting) are common initially but typically improve with slow titration
Continue Metformin
Metformin should be continued unless contraindicated 1. The KDIGO guidelines strongly recommend metformin for patients with type 2 diabetes and CKD with eGFR ≥30 mL/min/1.73 m² (Grade 1B recommendation) 1. Dose adjustments are only needed if eGFR falls below 45 mL/min/1.73 m².
Alternative Considerations (Lower Priority)
If GLP-1 RAs are not tolerated or contraindicated:
DPP-4 inhibitors (such as linagliptin or sitagliptin with dose adjustment) are reasonable alternatives 1, 2:
- Lower hypoglycemia risk
- Weight neutral
- No increased UTI risk
- However, they lack the cardiovascular and renal benefits of GLP-1 RAs
Do not use both a GLP-1 RA and DPP-4 inhibitor together—they work through similar mechanisms and combination provides no additional benefit 1.
Key Clinical Pitfalls to Avoid
Do not restart the SGLT2 inhibitor immediately without addressing the recurrent UTI pattern—while some data suggest continuation may be safe 3, the patient's repeated infections indicate poor tolerance
Avoid sulfonylureas as they increase hypoglycemia risk and lack cardiovascular/renal benefits 1
Monitor for GLP-1 RA side effects: Start with low doses and titrate slowly; most GI symptoms resolve within 4-8 weeks 1
Assess renal function before initiating therapy and monitor periodically, though most GLP-1 RAs require no dose adjustment 2
Consider insulin only if glycemic targets are not met with metformin plus GLP-1 RA, as it increases hypoglycemia risk and requires more intensive monitoring 4